Metabolic dysfunction-associated steatohepatitis (MASH) - Novo Nordisk
We are acting on our purpose to defeat serious chronic diseases by expanding our commitment in areas of high unmet need, including metabolic dysfunction-associated steatohepatitis (MASH). …
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
1 day ago · Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy ® …
Novo Nordisk will file semaglutide for MASH next year
2 days ago · Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, …
FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’
4 days ago · The Wegovy approval for the treatment of MASH with moderate-to-advanced scarring was granted to Novo Nordisk.
Wegovy® approved by FDA for the treatment of adults with …
3 days ago · About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for …
With key FDA nod in MASH, Novo's Wegovy scores 3rd indication
1 day ago · With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease.
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated ...
Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH).
Novo Nordisk A/S: Wegovy® approved in the US for the
3 days ago · Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH 15. August 2025 17:23 ET | Quelle: Novo Nordisk A/S
Novo’s Wegovy becomes first GLP-1 drug approved for MASH
1 day ago · Dive Brief: The Food and Drug Administration on Friday cleared a new use for Novo Nordisk’s Wegovy, granting accelerated approval of the popular weight loss drug in a common …
FDA, Health Canada reviewing semaglutide for liver disease MASH
May 5, 2025 · The U.S. Food and Drug Administration and Health Canada are reviewing Novo Nordisk ‘s requests to approve semaglutide’s under-the-skin formulation, at a dose of 2.4 mg, …
- Some results have been removed